MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accrued expenses
Stock-based compensation
Others
Negative Cash Flow Breakdown
Change in fair value of warrant ...
Prepaid expenses and other curre...
Operating lease liabilities
Effect of foreign currency on ca...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-8,217
-11,823
-7,718
-10,083
Depreciation
36
46
49
55
Amortization of right-of-use assets, operating leases
247
243
237
234
Non-cash interest expense
0
0
-496
603
Amortization of debt discount
60
68
182
0
Costs expensed upon the issuance of warrants
-
-
0
0
Change in fair value of warrant liabilities
-2,483
984
-1,262
1,811
Loss on issuance of warrants
-
-
0
0
Stock-based compensation
935
868
772
698
Gain on disposal of property and equipment
-
-
0
0
Prepaid expenses and other current assets
753
504
-106
344
Other long-term prepaid assets
-170
225
0
170
Accounts payable
627
-460
351
-3,544
Accrued expenses
1,465
-602
1,214
-3,202
Deferred research obligation
0
0
0
0
Operating lease liabilities
-252
-240
-232
-228
Proceeds from issuance of common stock warrants from march 2024 offering
-
-
0
0
Net cash used in operating activities
-8,165
-11,645
-6,797
-11,086
Proceeds from issuance of common stock warrants from july 2024 public offering
-
-
0
-
Purchases of property and equipment
-
-
16
0
Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs
-
-
13,393
-
Proceeds from sale of property and equipment
-
-
0
0
Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs
16,432
7,988
-
-
Proceeds from issuance of common stock from july 2024 public offering
-
-
0
-
Net cash used in investing activities
-
-
-16
0
Payment of offering costs for the issuance of common stock from at-the-market offering
-
61
-
-
Payment of warrant issuance costs
-
-
0
0
Proceeds from the exercise of common warrants
0
0
0
950
Proceeds from issuance of convertible note, net of issuance costs
-
-
0
0
Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs
-
-
-
11,385
Proceeds from issuance of common stock and common warrants from the january 2025 offering, net of issuance costs
0
0
0
0
Proceeds from the june 2025 promissory note, net of issuance costs
0
-
0
0
Proceeds from the exercise of stock options
17
100
4
88
Net cash provided by financing activities
16,510
8,027
4,863
9,572
Effect of foreign currency on cash and cash equivalents
-4
5
-96
39
Net increase in cash and cash equivalents
8,341
-3,613
-2,046
-1,475
Cash, cash equivalents and restricted cash at the beginning of the period
15,654
19,267
21,313
19,492
Cash, cash equivalents, and restricted cash at the end of the period
23,995
-
-
-
Cash and cash equivalents
23,480
-
-
-
Restricted cash
515
-
-
-
Total cash, cash equivalents and restricted cash
23,995
15,654
19,267
21,313
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock from...
$16,432K
Proceeds from the
exercise of stock options
$17K
(-70.18%↓ Y/Y)
Net cash provided by
financing activities
$16,510K
(-25.83%↓ Y/Y)
Net increase in cash
and cash...
$8,341K
(153.06%↑ Y/Y)
Canceled cashflow
$8,169K
Accrued expenses
$1,465K
(144.27%↑ Y/Y)
Stock-based compensation
$935K
(-23.80%↓ Y/Y)
Accounts payable
$627K
(-77.82%↓ Y/Y)
Amortization of right-of-use
assets, operating...
$247K
(-45.47%↓ Y/Y)
Other long-term
prepaid assets
-$170K
Amortization of debt discount
$60K
(71.43%↑ Y/Y)
Depreciation
$36K
(-64.00%↓ Y/Y)
Net cash used in
operating activities
-$8,165K
(57.18%↑ Y/Y)
Effect of foreign
currency on cash and cash...
-$4K
(-103.81%↓ Y/Y)
Canceled cashflow
$3,540K
Net loss
-$8,217K
(62.26%↑ Y/Y)
Change in fair value of
warrant liabilities
-$2,483K
(-281.77%↓ Y/Y)
Prepaid expenses and
other current assets
$753K
(154.29%↑ Y/Y)
Operating lease
liabilities
-$252K
(42.86%↑ Y/Y)
Buy us a coffee
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)